Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11
MW Martin, JY Lee, DR Lancia Jr, PY Ng, B Han… - Bioorganic & medicinal …, 2018 - Elsevier
MW Martin, JY Lee, DR Lancia Jr, PY Ng, B Han, JR Thomason, MS Lynes, CG Marshall…
Bioorganic & medicinal chemistry letters, 2018•ElsevierAbstract N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of
HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of
inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and
pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its
potential use as a therapeutic target for oncology and inflammation indications.
HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of
inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and
pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its
potential use as a therapeutic target for oncology and inflammation indications.
Abstract
N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its potential use as a therapeutic target for oncology and inflammation indications.
Elsevier
